Clinical Trial

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

Study acronym: ERASE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
ERASE is part of the MyeloMATCH initiative, Young Adult Basket and is a Tier 2 study. The study is comparing the use of Cytarabine to Cytarabine and Venetoclax, Daunorubicin/Cytarabine Liposome and Venetoclax, and Azacitidine and Venetoclax.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-25; most recent amendment 2024-06-29.
Trial Details
NCT Number NCT05628623
Lead Sponsor Eastern Cooperative Oncology Group
Collaborators: National Cancer Institute (NCI)
Conditions Leukemia, Myeloid, Acute
Enrollment 184 participants
Start Date 2024-10-23
Primary Completion 2026-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-07-03